Pharmaceuticals & Therapeutics

As AN2 Therapeutics bets its future on novel boron-based drugs, the appointment of Dr. Cameron Trenor signals a critical shift from promise to proof.

FDA clearance for Roche's pTau217 blood test isn't just a clinical win; it's a strategic move to dominate a $27B market by making diagnosis simple and scalable.

Takeda's ORZEYFUL, a first-in-class orexin agonist, wins approval in Japan, offering the first treatment for the root cause of Narcolepsy Type 1.

With a new patent, a bold asset pivot, and a top-tier banking partner, PharmAla Biotech is signaling a new phase of commercial maturity in psychedelic medicine.

A proposed SXSW panel on longevity medicine forces a crucial question: Are we on the verge of restoring youth, or just drowning in promises? We look at the science.

A $1M award for a novel drug targeting mitochondrial dysfunction is more than just funding; it's a bet on a new paradigm for fighting neurodegeneration.

With federal funds backing its Phase 3 trial for a first-in-class cannabis withdrawal drug, PleoPharma offers a new model for biotech investment.

With positive Phase 1 results, AC Immune's NLRP3 inhibitor not only targets neuro-inflammation but also bolsters the company's independent strategy.

A new AI-designed eye drug gets clinical trial clearance, validating Matwings' iterative platform and signaling a major shift in biopharma R&D strategy.

A new campaign pressures NB's government to fight federal rules limiting nicotine pouches to pharmacies, igniting a debate on rural access and harm reduction.

A new campaign in Newfoundland challenges federal rules, asking why quitting aids are harder to buy than cigarettes, and exposing a booming black market.

Telix's impressive H1 results show more than just profit; they reveal a calculated strategy to build a global radiopharmaceutical powerhouse.

A groundbreaking clinical trial is testing whether a common bone-strengthening drug can 'unmask' and eliminate the hidden HIV reservoir, a critical barrier to a cure.

Unauthorized antibiotics and ED drugs sold from a Montreal store reveal a dangerous black market that bypasses health regulations and puts consumers at risk.

A top exec's move from a device giant to a drug startup signals a major shift. Charles Anderson analyzes why hardware's limits in fighting infection are now biotech's biggest opportunity.

The dermatology giant posts strong revenue but dips in profit, channeling funds into high-impact acquisitions and R&D for underserved skin conditions.

Coultreon Biopharma's strategic hire of Dr. Prista Charuworn signals a major push to advance its novel SIK3 inhibitor in the crowded autoimmune market.

Beyond beta-blockers, a new class of targeted therapies is revolutionizing hypertrophic cardiomyopathy care, sparking a fierce corporate race for market dominance.

20/20 BioLabs' record revenue is just the surface. Underneath, the company is building an AI-powered health network, starting with firefighters and cities.

The sickle cell drugmaker engineered a stunning Q2 profit, but a deep dive reveals a radical strategic bet on outsourcing its commercial backbone.